Ozempic vs Wegovy: Complete Cost, Dosage & Results Comparison (2026)

The Core Fact: Same Molecule, Different Dose

Both Ozempic and Wegovy contain semaglutide — a GLP-1 receptor agonist developed by Novo Nordisk. They work through identical mechanisms: slowing gastric emptying, reducing appetite, and increasing feelings of fullness through GLP-1 receptor activation in the brain and gut.

The critical difference is dosage:

Ozempic: Approved for type 2 diabetes. Doses of 0.5mg, 1mg, and 2mg weekly.
Wegovy: Approved for chronic weight management. Maintenance dose of 2.4mg weekly — 20% higher than Ozempic's maximum approved dose.

That 0.4mg difference between Ozempic's maximum (2mg) and Wegovy's maintenance (2.4mg) is clinically meaningful. The STEP-1 and SUSTAIN-6 trials show that weight loss is dose-dependent with semaglutide — more drug means more appetite suppression and, generally, more weight loss.

Head-to-Head Comparison Table

Factor	Ozempic	Wegovy
Active Ingredient	Semaglutide	Semaglutide
FDA Approval	Type 2 Diabetes (2017)	Chronic Weight Management (2021)
Maintenance Dose	1mg–2mg weekly	2.4mg weekly
Avg Weight Loss	10–12% body weight (SUSTAIN)	~15% body weight (STEP-1)
List Price / Month	~$900–$1,000	~$1,300–$1,400
Insurance Coverage	Often covered for T2D	Limited coverage for obesity
Manufacturer Savings	~$25/month (for eligible)	~$0–$500/month (for eligible)
Injection Frequency	Once weekly	Once weekly
Pen Type	Pre-filled pen	Pre-filled pen
Titration Duration	4–8 weeks to max dose	16–20 weeks to 2.4mg

Weight Loss: How Much More Does Wegovy Deliver?

In the landmark clinical trials, Wegovy's higher dose demonstrated meaningfully better weight loss:

14.9% vs 10.5%

Average body weight lost: Wegovy 2.4mg (STEP-1) vs Ozempic 1mg (SUSTAIN-1)
Both over 68 weeks

For a 220-lb person, that's the difference between losing about 33 lbs (Wegovy) versus 23 lbs (Ozempic 1mg) — a 10-lb difference that matters to many patients.

However, it's important to note that these trials had different populations and study designs. Direct head-to-head trials at these specific doses for weight loss are limited. The real-world difference may be slightly smaller or larger depending on individual factors.

FDA Approval and Off-Label Use

Here's where things get complicated. Ozempic is frequently prescribed off-label for weight loss — meaning doctors legally prescribe it for a purpose (weight loss) that isn't its FDA-approved indication (type 2 diabetes).

Off-label prescribing is legal and common in medicine. However, it creates several practical issues:

Insurance coverage: Most insurance plans will cover Ozempic for type 2 diabetes but not for weight loss (off-label). If you're prescribed Ozempic specifically for weight loss and you don't have T2D, your insurance likely won't cover it.
Supply shortages: The surge in off-label Ozempic use for weight loss created significant supply shortages in 2022–2024 that affected patients who needed it for T2D. While supply has improved, this remains a concern.
Lower maximum dose: The highest FDA-approved Ozempic dose is 2mg. Wegovy allows 2.4mg — the dose shown to produce the best weight loss outcomes.

Cost Comparison: The Real-World Numbers

Both medications are expensive without insurance. Here's a realistic breakdown:

Ozempic Cost

List price: $900–$1,000 per month without insurance
With commercial insurance (T2D diagnosis): Often covered, copays of $25–$150/month are common
Ozempic Savings Card: Eligible commercially insured patients may pay as little as $25/month
Without insurance (weight loss use): Full list price, often $900+/month
Compounded semaglutide: While FDA has removed most compounded options from the market, this created a gray market that reduced costs to $200–$500/month for some patients (quality varies significantly)

Wegovy Cost

List price: $1,300–$1,400 per month without insurance
With commercial insurance: Coverage is improving but still inconsistent. Some plans cover it, many don't.
Wegovy Savings Card: Eligible patients may pay as little as $0/month (income and insurance restrictions apply)
Medicare/Medicaid: Medicare Part D now covers Wegovy for cardiovascular risk reduction (SELECT trial outcomes). Coverage varies by plan.

The SELECT trial (published 2023) showed semaglutide 2.4mg reduced major cardiovascular events by 20% in overweight/obese adults with existing cardiovascular disease — independent of weight loss alone. This resulted in Wegovy receiving an additional FDA indication for cardiovascular risk reduction and expanded Medicare coverage.[2]

Insurance Coverage: The Deciding Factor for Most People

For many patients, insurance coverage is the single most important factor in the Ozempic vs Wegovy decision. The landscape is evolving rapidly:

When Ozempic is more accessible

You have a type 2 diabetes diagnosis — Ozempic is approved and typically covered
Your insurance plan covers diabetes medications but not obesity medications
Your provider is familiar with off-label prescribing for weight management

When Wegovy is more accessible

You have a BMI ≥30 (or ≥27 with weight-related comorbidities) and no T2D diagnosis
Your insurance plan now covers anti-obesity medications (this list is growing)
You have cardiovascular disease and BMI ≥27 (SELECT trial indication)
Your employer-sponsored plan covers Wegovy (more common now)

Side Effects: Are They Different?

Since Ozempic and Wegovy are the same molecule, their side effect profiles are nearly identical. The primary difference is that Wegovy's higher maximum dose (2.4mg vs 1–2mg) tends to produce more pronounced side effects in some patients.

The most common side effects across both medications:

Nausea (most common, affects ~40–44% of users)
Diarrhea
Vomiting
Constipation
Abdominal discomfort

Most side effects peak during dose escalation and diminish at steady-state doses. Read our complete guide to managing semaglutide side effects for detailed strategies.

Which Should You Choose?

The decision often comes down to your clinical situation, insurance, and goals:

If you have type 2 diabetes: Ozempic is the appropriate choice — it's approved, often covered, and provides meaningful weight loss benefit alongside glucose control.
If you're focused primarily on weight loss: Wegovy at 2.4mg provides the best evidence-based outcomes for weight loss specifically.
If cost is the primary concern: Ozempic with a T2D diagnosis (and thus insurance coverage) is often the most affordable route. Without T2D, costs are similar and high for both.
If you have cardiovascular disease: Wegovy now has an approved indication for CV risk reduction — check with your cardiologist and insurance.

Talk to your prescriber

The right medication depends on your full medical history, current diagnoses, insurance situation, and personal health goals. This article provides educational context — your prescribing physician should make the final recommendation.

Calculate Your Projected Results on Either Medication

Enter your stats and compare projected weight loss on Ozempic, Wegovy, Mounjaro, and Zepbound.

Try the Free Calculator →

References

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.